Company Filing History:
1 out of 38 
1 out of 15 
1 out of 280 
Years Active: 2025
Title: Maëva Chauvin: Innovator in Ovarian Cancer Research
Introduction
Maëva Chauvin is a notable inventor based in Montpellier, France. He has made significant contributions to the field of ovarian cancer research, particularly through his innovative patent related to anti-Müllerian inhibiting substance antibodies.
Latest Patents
Chauvin holds a patent for "Anti-müllerian inhibiting substance antibodies and uses thereof." This patent explores the potential therapeutic targets in ovarian carcinoma, focusing on the Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway. His research indicates that ALK2 and ALK3 are the primary MIS type I receptors involved in MIS signaling at varying concentrations. The findings suggest that high MIS concentrations can lead to apoptosis and reduced clonogenic survival, while low concentrations may enhance cancer cell viability. Notably, the anti-MIS antibody B10 has been shown to inhibit the pro-survival effects of MIS, paving the way for innovative therapeutic approaches.
Career Highlights
Throughout his career, Maëva Chauvin has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and the Institut Régional du Cancer de Montpellier. His work has been pivotal in advancing the understanding of ovarian cancer and its treatment.
Collaborations
Chauvin has collaborated with notable colleagues, including André Pelegrin and Bruno Robert, contributing to the collective knowledge and research in the field of cancer therapy.
Conclusion
Maëva Chauvin's innovative work in ovarian cancer research highlights the importance of targeted therapies and the potential for new treatment strategies. His contributions continue to influence the field and offer hope for improved patient outcomes.